Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching

Overview of attention for article published in Applied Health Economics and Health Policy, February 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

So far, Altmetric has seen 1 public wall post.

#HealthEconJA Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.